MetLife Investment Management LLC Boosts Stock Holdings in Ventyx Biosciences, Inc. (NASDAQ:VTYX)

MetLife Investment Management LLC raised its position in shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) by 76.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 26,731 shares of the company’s stock after acquiring an additional 11,543 shares during the period. MetLife Investment Management LLC’s holdings in Ventyx Biosciences were worth $59,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also made changes to their positions in the company. Catalina Capital Group LLC purchased a new position in shares of Ventyx Biosciences during the fourth quarter valued at approximately $25,000. AXQ Capital LP purchased a new position in Ventyx Biosciences during the fourth quarter valued at approximately $29,000. Palumbo Wealth Management LLC raised its position in shares of Ventyx Biosciences by 97.1% in the 4th quarter. Palumbo Wealth Management LLC now owns 23,932 shares of the company’s stock worth $52,000 after acquiring an additional 11,792 shares in the last quarter. Wells Fargo & Company MN grew its stake in Ventyx Biosciences by 23.3% in the fourth quarter. Wells Fargo & Company MN now owns 41,170 shares of the company’s stock valued at $90,000 after purchasing an additional 7,768 shares during the last quarter. Finally, American Century Companies Inc. raised its holdings in Ventyx Biosciences by 12.4% in the fourth quarter. American Century Companies Inc. now owns 67,329 shares of the company’s stock worth $147,000 after purchasing an additional 7,414 shares in the last quarter. 97.88% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “neutral” rating on shares of Ventyx Biosciences in a research report on Tuesday, January 14th.

Ventyx Biosciences Trading Up 6.0 %

Shares of Ventyx Biosciences stock opened at $1.24 on Friday. Ventyx Biosciences, Inc. has a twelve month low of $0.78 and a twelve month high of $5.66. The firm’s 50-day moving average price is $1.22 and its 200 day moving average price is $1.79. The firm has a market capitalization of $88.24 million, a PE ratio of -0.53 and a beta of 0.73.

Ventyx Biosciences (NASDAQ:VTYX) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.39) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.09. On average, sell-side analysts predict that Ventyx Biosciences, Inc. will post -2.09 EPS for the current fiscal year.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.